Drugs / BIIB122
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06264440 | Feb → Jun 2024 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT05229562 | Feb → Sep 2022 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT05119790 | Aug → Nov 2021 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT05005338 | Jul → Sep 2021 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT04056689 | Jul 2019 → Dec 2020 | Parkinson disease | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT04557800 | Nov 2017 → Feb 2021 | — | Denali Therapeutics Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06602193 | Oct 2024 → Mar 2027 expected | Parkinson disease | Denali Therapeutics Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05348785 | Apr 2022 → Mar 2026 | Parkinson disease | Biogen | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05418673 | Aug 2022 → Jul 2023 | Parkinson disease | Biogen | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIIB122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06602193 ↗ |
| Known as | DNL151 | “The mass balance, excretion, and PK of BIIB122 (DNL151) will be used to evaluate AME.” NCT05119790 ↗ |
| Action | Inhibit | “small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2)” NCT05348785 ↗ |
| Modality | Small molecule | “BIIB122 is an investigational central nervous system-penetrant small molecule inhibitor” NCT05348785 ↗ |
| Route | Oral | “multiple oral doses of DNL151” NCT04056689 ↗ |
| Target | LRRK2 | “inhibitor of leucine-rich repeat kinase 2 (LRRK2)” NCT05348785 ↗ |